FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Gao JJ, Osgood CL, Gong Y, Zhang H, Bloomquist EW, Jiang X, Qiu J, Yu J, Song P, Rahman NA, Chiu HJ, Ricks TK, Rizvi F, Hou S, Wilson W, Abukhdeir AM, Seidman J, Ghosh S, Philip R, Pierce WF, Bhatnagar V, Kluetz PG, Pazdur R, Beaver JA, Amiri-Kordestani L.
Gao JJ, et al. Among authors: rizvi f.
Clin Cancer Res. 2021 Apr 15;27(8):2126-2129. doi: 10.1158/1078-0432.CCR-20-3474. Epub 2020 Nov 13.
Clin Cancer Res. 2021.
PMID: 33188141